Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-7366 in Advanced Solid Tumors
NCT05121948Phase 1Terminated
- Sponsor
- HiberCell
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC-7366 in solid tumor (advanced stage), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and 3 more (8 arms), sponsored by HiberCell. Primary endpoints: Maximum Tolerated Dose at 18 months, Recommended Phase 2 Dose at 18 months and 2 more. Started Feb 2022; status: terminated.
02
Drugs
HC-7366
03
Conditions
solid tumor (advanced stage)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT05121948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121948.